
CDLX Valuation
Cardlytics Inc
- Overview
- Forecast
- Valuation
- Earnings
CDLX Relative Valuation
CDLX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CDLX is overvalued; if below, it's undervalued.
Historical Valuation
Cardlytics Inc (CDLX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -23.95. The fair price of Cardlytics Inc (CDLX) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 1.11 USD , Cardlytics Inc is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price:1.11
Fair
Undervalued
-1.75
PE
1Y
3Y
5Y
Trailing
Forward
-156.23
EV/EBITDA
Cardlytics Inc. (CDLX) has a current EV/EBITDA of -156.23. The 5-year average EV/EBITDA is -69.24. The thresholds are as follows: Strongly Undervalued below -1105.30, Undervalued between -1105.30 and -587.27, Fairly Valued between 448.79 and -587.27, Overvalued between 448.79 and 966.82, and Strongly Overvalued above 966.82. The current Forward EV/EBITDA of -156.23 falls within the Historic Trend Line -Fairly Valued range.
-8.21
EV/EBIT
Cardlytics Inc. (CDLX) has a current EV/EBIT of -8.21. The 5-year average EV/EBIT is 25.94. The thresholds are as follows: Strongly Undervalued below -400.15, Undervalued between -400.15 and -187.10, Fairly Valued between 238.98 and -187.10, Overvalued between 238.98 and 452.02, and Strongly Overvalued above 452.02. The current Forward EV/EBIT of -8.21 falls within the Historic Trend Line -Fairly Valued range.
0.25
PS
Cardlytics Inc. (CDLX) has a current PS of 0.25. The 5-year average PS is 4.34. The thresholds are as follows: Strongly Undervalued below -5.77, Undervalued between -5.77 and -0.72, Fairly Valued between 9.40 and -0.72, Overvalued between 9.40 and 14.45, and Strongly Overvalued above 14.45. The current Forward PS of 0.25 falls within the Historic Trend Line -Fairly Valued range.
13.88
P/OCF
Cardlytics Inc. (CDLX) has a current P/OCF of 13.88. The 5-year average P/OCF is -16.10. The thresholds are as follows: Strongly Undervalued below -427.29, Undervalued between -427.29 and -221.69, Fairly Valued between 189.50 and -221.69, Overvalued between 189.50 and 395.10, and Strongly Overvalued above 395.10. The current Forward P/OCF of 13.88 falls within the Historic Trend Line -Fairly Valued range.
-4.43
P/FCF
Cardlytics Inc. (CDLX) has a current P/FCF of -4.43. The 5-year average P/FCF is 791.07. The thresholds are as follows: Strongly Undervalued below -5169.27, Undervalued between -5169.27 and -2189.10, Fairly Valued between 3771.24 and -2189.10, Overvalued between 3771.24 and 6751.41, and Strongly Overvalued above 6751.41. The current Forward P/FCF of -4.43 falls within the Historic Trend Line -Fairly Valued range.
Cardlytics Inc (CDLX) has a current Price-to-Book (P/B) ratio of 0.98. Compared to its 3-year average P/B ratio of 1.59 , the current P/B ratio is approximately -38.18% higher. Relative to its 5-year average P/B ratio of 4.31, the current P/B ratio is about -77.15% higher. Cardlytics Inc (CDLX) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -10.12%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -6.80% , the current FCF yield is about -100.00% lower.
0.98
P/B
Median3y
1.59
Median5y
4.31
-4.07
FCF Yield
Median3y
-10.12
Median5y
-6.80
Competitors Valuation Multiple
The average P/S ratio for CDLX's competitors is 0.52, providing a benchmark for relative valuation. Cardlytics Inc Corp (CDLX) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of -9.17%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Performance Decomposition
1Y
3Y
5Y
Market capitalization of CDLX decreased by 71.61% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -6.11 to -14.68.
The secondary factor is the Revenue Growth, contributed -9.17%to the performance.
Overall, the performance of CDLX in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch

CHSN
Chanson International Holding
2.260
USD
+2.73%

STRS
Stratus Properties Inc
19.480
USD
+8.04%

ZNTL
Zentalis Pharmaceuticals Inc
1.990
USD
+6.42%

DOUG
Douglas Elliman Inc
2.660
USD
+6.83%

CSPI
CSP Inc
12.740
USD
+7.92%

CBNA
Chain Bridge Bancorp Inc
28.380
USD
+3.96%

RMBL
RumbleOn Inc
0
USD
+37.69%

CHRS
Coherus Oncology Inc
1.230
USD
+8.85%

PEBK
Peoples Bancorp of North Carolina Inc
31.850
USD
+7.42%

IBAC
IB Acquisition Corp
10.510
USD
0.00%
FAQ

Is Cardlytics Inc (CDLX) currently overvalued or undervalued?
Cardlytics Inc (CDLX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -23.95. The fair price of Cardlytics Inc (CDLX) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 1.11 USD , Cardlytics Inc is Undervalued By Fair .

What is Cardlytics Inc (CDLX) fair value?

How does CDLX's valuation metrics compare to the industry average?

What is the current P/B ratio for Cardlytics Inc (CDLX) as of Aug 23 2025?

What is the current FCF Yield for Cardlytics Inc (CDLX) as of Aug 23 2025?

What is the current Forward P/E ratio for Cardlytics Inc (CDLX) as of Aug 23 2025?
